peter attia on semaglutide Could GLP-1s impact aging and cognitive health?

320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape

26.31

★★★★☆4.8 (126)

A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that's not the question we ought to be asking

22.56

★★★★★4.9 (98)

A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that's not the question we ought to be asking

27.27

★★★★★5.0 (157)

A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that's not the question we ought to be asking

27.15

★★★★★4.7 (84)

246 - AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent - The Peter Attia Drive

22.47

★★★★★4.9 (203)

Micro-dosing GLP-1 receptor agonists (drugs like semaglutide/Ozempic) could offer meaningful benefits while minimizing harmful side effects., There’s no doubt these drugs are incredibly effective for

21.44

★★★★★5.0 (176)

Revising our earlier interpretation of SELECT trial data in light of new analyses. To receive content like this directly in your inbox, click the link in my bio and select “Sign Up

23.88

★★★★★4.8 (132)